AcelRx Pharmaceuticals Inc (ACRX) Insider Lawrence G. Hamel Sells 6,953 Shares

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) insider Lawrence G. Hamel sold 6,953 shares of the company’s stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $4.50, for a total transaction of $31,288.50. Following the completion of the transaction, the insider now owns 24,371 shares in the company, valued at approximately $109,669.50. The sale was disclosed in a legal filing with the SEC, which is available through this link.

NASDAQ:ACRX traded down $0.08 during trading hours on Thursday, reaching $3.97. The company’s stock had a trading volume of 17,659 shares, compared to its average volume of 777,256. The stock has a market capitalization of $251.49 million, a PE ratio of -3.64 and a beta of 2.09. AcelRx Pharmaceuticals Inc has a one year low of $1.55 and a one year high of $5.75. The company has a current ratio of 4.01, a quick ratio of 3.96 and a debt-to-equity ratio of -0.15.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.01). The company had revenue of $0.82 million for the quarter, compared to analysts’ expectations of $0.93 million. sell-side analysts forecast that AcelRx Pharmaceuticals Inc will post -0.83 earnings per share for the current fiscal year.

A number of brokerages recently issued reports on ACRX. Cantor Fitzgerald reiterated a “buy” rating and issued a $6.00 price target on shares of AcelRx Pharmaceuticals in a research note on Thursday, September 20th. LADENBURG THALM/SH SH began coverage on shares of AcelRx Pharmaceuticals in a research note on Thursday, August 16th. They issued a “buy” rating and a $7.00 price target on the stock. Zacks Investment Research downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 14th. HC Wainwright reaffirmed a “buy” rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 7th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, August 3rd. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $5.21.

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in AcelRx Pharmaceuticals by 2.7% in the second quarter. BlackRock Inc. now owns 673,115 shares of the specialty pharmaceutical company’s stock worth $2,271,000 after purchasing an additional 17,737 shares in the last quarter. Lincoln Capital Corp bought a new stake in AcelRx Pharmaceuticals in the second quarter worth $116,000. Northern Trust Corp boosted its holdings in AcelRx Pharmaceuticals by 60.8% in the first quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock worth $192,000 after purchasing an additional 34,584 shares in the last quarter. GSA Capital Partners LLP bought a new stake in AcelRx Pharmaceuticals in the first quarter worth $113,000. Finally, Granite Investment Partners LLC bought a new stake in AcelRx Pharmaceuticals in the second quarter worth $182,000. Hedge funds and other institutional investors own 8.59% of the company’s stock.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Read More: How to Profit and Limit Losses With Stop Orders

Insider Buying and Selling by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply